Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial

What Was Tested

Researchers studied Insulin Glargine and Insulin Aspart in this randomized controlled trial publication.

The researchers compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial.

Who Took Part

According to the abstract, 40 patients were involved.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Insulin Glargine and the comparison at some point, usually with a gap in between.

BG, counter-regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24 h after exercise.

What Was Measured

Topics PubMed links to this paper include Circadian Rhythm, Diabetes Mellitus, Type 1, Exercise Test, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents and Insulin Aspart.

Author keywords: glycaemic control, insulin therapy and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Glargine and Insulin Aspart in 40 patients.

The publication is from 2016 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Glargine compound page and the Insulin Aspart compound page.